Mechanism of Action of Levosimendan and Its Adverse Effects
Levosimendan is a calcium sensitizer that improves cardiac contractility by binding to troponin-C in cardiomyocytes, exerts significant vasodilation through ATP-sensitive potassium channel opening, and has mild phosphodiesterase-3 inhibitory action. 1
Mechanism of Action
Levosimendan operates through three distinct pharmacological pathways:
Primary Mechanism: Calcium Sensitization
The drug enhances myocardial contractility by calcium-dependent binding to cardiac troponin-C, which increases the sensitivity of contractile proteins to calcium without raising intracellular calcium levels 1, 2, 3. This mechanism is fundamentally different from traditional inotropes because it does not increase cytosolic calcium concentrations, making it less arrhythmogenic 4.
Vasodilatory Effects
Levosimendan produces significant vasodilation mediated through ATP-sensitive potassium channel opening in vascular smooth muscle 1, 2. This results in reductions in systemic vascular resistance, pulmonary vascular resistance, and pulmonary wedge pressure 1.
Additional Mechanism
The drug has mild phosphodiesterase-3 (PDE-3) inhibitory action 1, 3, though this effect appears less clinically significant at therapeutic concentrations.
Key Pharmacological Advantage
The inotropic effect is independent of β-adrenergic stimulation, making levosimendan an effective alternative for patients on β-blocker therapy 1. The hemodynamic response is maintained over several days due to an active metabolite (OR-1896) with an elimination half-life of approximately 80 hours 3.
Hemodynamic Effects
When administered to patients with acutely decompensated heart failure, levosimendan produces:
- Increased cardiac output and stroke volume
- Reduced pulmonary wedge pressure
- Decreased systemic and pulmonary vascular resistance
- Reduced pulmonary artery pressure 1
Adverse Effects
Most Common Adverse Effects
Levosimendan treatment is associated with a slight increase in heart rate and a decrease in blood pressure, especially if a loading dose is administered 1.
The most frequently reported adverse events include:
- Hypotension - the most clinically significant adverse effect, particularly when a loading bolus is given 2, 3
- Tachycardia - related to the vasodilatory properties and reflex sympathetic activation 2
- Headache - commonly reported, likely secondary to vasodilation 2, 3
- Atrial fibrillation 2
- Hypokalemia 2
Critical Dosing Consideration to Minimize Adverse Effects
In patients with systolic blood pressure <100 mmHg, the infusion should be started without a bolus dose to avoid hypotension 1. This is a crucial safety measure emphasized across multiple guidelines.
Standard Dosing Protocol
- Optional loading dose: 3-12 μg/kg over 10 minutes (only if SBP ≥100 mmHg)
- Continuous infusion: 0.05-0.2 μg/kg/min for 24 hours
- The infusion rate may be increased once hemodynamic stability is confirmed 1
Safety Profile Compared to Traditional Inotropes
Unlike conventional β-agonist inotropes or PDE-3 inhibitors, levosimendan:
- Does not increase myocardial oxygen consumption significantly 2
- Is less arrhythmogenic due to its calcium-independent mechanism 4
- Does not prolong diastolic relaxation 4
- Maintains efficacy during concurrent β-blocker therapy 1, 3
Important Clinical Caveat
Levosimendan is a vasodilator and is not suitable for treatment of patients with hypotension (SBP <85 mmHg) or cardiogenic shock unless used in combination with other inotropes or vasopressors 5. The vasodilatory properties that contribute to afterload reduction can exacerbate hypotension in already compromised patients.